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Title: Immunohistochemistry patterns of SARS-CoV-2 Deaths in Forensic Autopsies
Abstract
SARS-CoV-2 infection was a leading cause of death in 2020 worldwide.  It can evolve determining 
sudden dyspnea and death without hospitalization and/or a nasopharyngeal swab. These cases can 
need the intervention of forensic pathologists in order to identify causes of death and to clarify 
malpractice claims. For these reasons, it would be useful to identify immunohistochemistry patterns 
of SARS-CoV-2 deaths. Thus, the authors described immunohistochemistry findings of two 
Patients: perivascular recruitment of T-cells in lung parenchyma, massive activation of cytotoxic 
cells (especially in spleen’s parenchyma), and diffuse platelet aggregation in medium/small vessels. 
In addition, they analyzed these data in the light of the scientific literature, pointing out meaningful 
immunohistochemistry patterns in order to better understand SARS-CoV-2 pathophysiology 
process and to clearly identify causes/contributing factors of death in forensic routine.  
Key Words: SARS-CoV-2; immunohistochemistry; forensic pathology; immunology; 
lymphocytes; cytotoxic cells
1. Introduction
SARS-CoV-2 infection was a leading cause of death in 2020 worldwide (and it is predictable that 
this will also last in 2021) [1]. The virus can be responsible for a brief period of flu-like signs and/or 
symptoms that – especially in patients with multiple comorbidities – can evolve determining sudden 
dyspnea and death without hospitalization and/or a nasopharyngeal swab. These cases can need the 
intervention of forensic pathologists in order to identify causes of death and to clarify malpractice 
claims [2].
In the light of the above, the authors described immunohistochemistry (IHC) microscopic findings 
of two autopsies of patients acutely deceased by SARS-CoV-2 infection. The latter findings were 
not altered by effects of intensive care therapy (i.e. mechanical ventilation and drug administration). 
Their aim was also to identify new IHC insights of SARS-CoV-2 infection in order to better 
understand SARS-CoV-2 pathophysiology process and to facilitate the identification of 
causes/contributing factors of death in forensic routine.
2. Case Report 
Patient 1 was a 66-year-old-man. His medical history was positive for alcohol abuse, multiple 
cerebral ischemic events, and dementia. Patient 2 was an 83-year-old-woman affected by obesity 
and senile dementia. Both patients resided in the same nursing home. They showed fever (> 38°C) 
respectively for five and seven days, and they suddenly died despite antibiotics and paracetamol 
administration. They underwent neither ante-mortem SARS-CoV-2 tests nor intensive care 
procedures. Other information about their clinical course was not available. Post-mortem SARS-
CoV-2 real time reverse transcriptase polymerase chain reaction was positive in both cases. 
Forensic autopsies were requested by the Judicial Authority in order to clarify causes of death and 
malpractice claims. Autopsies revealed intensive lungs’ congestion. In both cases, at histology 
lungs’ hematoxylin and eosin stain yielded common signs of SARS-CoV-2 infection (diffuse 
alveolar damage, pneumocyte hyperplasia, intra-alveolar fibrinous exudates, dense hyaline 
membranes). For these reasons, forensic pathologists signed as cause of death acute respiratory 
distress syndrome (ARDS) by SARS-CoV-2 infection (Coronavirus Disease 2019 – COVID19). In 
both cases, medical malpractice claims were excluded because the deaths occurred during the first 
weeks of the pandemic, when useful indications about COVID19 therapy were not yet available.
In addition, immunohistochemistry (IHC) was performed yielding the following results (IHC was 
conducted in accordance with the indication of the scientific literature [3,4]; in particular, antibodies 
against CD3 (CD3 Monoclonal Antibody - LN10 - from Leica Biosystems), TIA1 (TIA1 
Monoclonal Antibody - 2G9A10F5 - from Beckman Coulter), CD20 (CD20 Monoclonal Antibody - 
L26 - Leica Biosystems), and CD61 (CD61 Monoclonal Antibody - 2F2 - from Beckman Coulter) 
were used. They were applied on formalin-fixed and paraffin-embedded samples after proper 
deparaffinization, rehydration, and heating. In the negative control reactions, the antibodies resulted 
in complete absence of staining).
2.1 Immunohistochemistry: CD3
CD3 is a protein complex expressed on T-lymphocytes’ surface [5]. In both cases, IHM for CD3 
identified T-lymphocytes’ diffuse perivascular recruitment in lungs (Figure 1). 
2.2 Immunohistochemistry: TIA1
TIA1 is a molecule – stored in cytotoxic granules of natural killer (NK) cells and cytotoxic T CD8 
lymphocytes – that possesses nucleolytic activity. [6]. In the reported cases, IHM for TIA1 showed 
cytotoxic cell focal infiltration in vessels and in perivascular spaces. In addition, this IMH reaction 
revealed massive and diffuse presence of cytotoxic cells in spleen’s parenchyma of Patient 2 
(Figure 1).
2.3 Immunohistochemistry: CD20
CD20 is a surface protein which is expressed by B-lymphocytes [7]. In both Patients, IMH for 
CD20 did not revealed specific recruitment of B-lymphocytes in lungs, heart, spleen, and kidneys.
2.4 Immunohistochemistry: CD61
CD61 is a molecule stored in α-granules of platelets. Its function is to constitute the most abundant 
platelet adhesion receptor (glycoprotein IIb/IIIa integrin) of this cell population [8]. In the reported 
cases, IHC for CD61 revealed diffuse platelet aggregation in medium/small vessels of pulmonary 
parenchyma. In addition, the same finding was focally present in myocardium and kidneys of 
Patient 2. In Patients 1, diffuse platelet aggregates were pointed out in small vessels of lungs’ hilar 
lymph nodes (Figure 2 and 3).
Comparative images of lungs, heart, spleen, and kidneys at histology (hematoxylin and eosin stain) 
are available in Figure 4.
3. Discussion
Until now, the immunology of SARS-CoV-2 infection is not yet completely understood. For 
example, multiple studies tried to identify virus’ impact on lymphocytes’ activity highlighting “the 
occurrence of lymphopenia with drastically reduced numbers of both CD4 and CD8 T cells in 
moderate and severe COVID-19 cases” [9]. This reduction (especially for CD8 T cells) also seems 
to correlate with severity and mortality of SARS-CoV-2 disease.  Even if this occurrence was 
already reported for other viral infections, its causes remain elusive (direct SARS-CoV-2 infection 
of T cells was not demonstrated) [9]. Some authors suggested that T cell reduction in peripheral 
blood may depend on their extensive recruitment in the site of the infection, contributing to SARS-
CoV-2 infection’s pathophysiologic progression. Talking about B-lymphocytes in SARS-CoV-2 
infection, it is known that the virus triggers a significant B cell response characterized by the rapid 
increase of virus-specific IgM, IgG and IgA, and neutralizing IgG antibodies, even if their kinetics 
are not yet completely understood [9,10]. In addition, until now it is not clear if antibodies towards 
the virus can contribute to determine pathology progression [9,11]. 
Regarding lymphocytes’ role in SARS-CoV-2 infection, in the scientific literature histologic 
evaluations of autopsies’ samples and biopsies of infected patients demonstrated extensive 
lymphocyte infiltration in the lungs [12]. In particular, Dettmeyer and colleagues recently described 
this infiltration as localized near lungs’ capillaries (lymphocytic capillaritis), adding meaningful 
insights to the scientific literature [13]. This manuscript allowed to identify that the aforementioned 
infiltration was principally determined by T cells which were diffusely recruited in perivascular 
areas of lungs. Thus, these findings seem to suggest a predominant role of T- lymphocytes in lungs’ 
SARS-CoV-2 pathophysiology, supporting the abovementioned hypothesis (i.e. T cell reduction in 
peripheral blood may depend on their extensive recruitment in the site of the infection, contributing 
to SARS-CoV-2 infection’s pathophysiologic progression). On the contrary, even if B-
lymphocytes’ activation has been extensively reported in the scientific literature, the present report 
does not point out accumulation/recruitment of B cells in lungs, heart, spleen, and kidneys of both 
Patients. 
Previous studies about cytotoxic cells’ activity in SARS-CoV-2 infection identified a significant 
reduction in peripheral blood of NKs and T CD8 lymphocytes [14]. In particular, the scientific 
literature pointed out that the activation of specific molecular pathway may induce their extensive 
recruitment in lungs from peripheral blood, causing their progressive consumption in moderate and 
severe forms of SARS-CoV-2 disease [9]. Indeed, it is well known that cytotoxic cells are 
fundamental mediators of the immune response in viral infections [9,14]. These statements are 
confirmed by the present manuscript. Indeed, in both Patients cytotoxic cell infiltration in lungs was 
focally present in vessels and in perivascular spaces. In addition, in Patient 2’s spleen it was 
highlighted a meaningful finding: massive and diffuse presence of cytotoxic cells. The latter 
microscopic finding is uncommon, because TIA1 positive cells are difficultly distinguishable in 
spleen’s physiologic parenchyma. This peculiar microscopic feature seems to concord with the 
scientific literature [14]. Indeed, it can be suggested that this phenomenon was caused by the 
massive consumption of cytotoxic cells in SARS-CoV-2 infected patients.
SARS-CoV-2 ability to alter coagulation homeostasis (especially in medium/small vessels: micro-
thrombosis) has been reported in the scientific literature, pointing out that severe parenchymal 
injury can be determined by microvasculature’s involvement. The latter was early identified as 
responsible for disease’s progression [15,16], observing that infected patients were characterized by 
“profound hypoxia which was out of proportion to the preserved lung mechanics suggestive of 
significant pulmonary shunting, raising the possibility of a lung injury mechanism different from 
that of traditional ARDS” [17]. This statement was confirmed by Ackerman and colleagues. They 
compared lungs of influenza A infected patients against SARS-CoV-2 ones, revealing as micro-
thrombi were more prevalent in SARS-CoV-2 disease [18]. In the literature, the reasons of micro-
thrombosis are not completely understood, even if direct and/or indirect endothelial damage seems 
to be the trigger of this phenomenon. This manuscript confirmed the abovementioned data. Indeed, 
at IHC microscopic evaluations of Patients’ organs, impressive finding was the occurrence of 
diffuse platelet aggregation in medium/small vessels of pulmonary parenchyma. Similar findings 
were present: focally in myocardium and kidneys of Patient 2; diffusely in Patient 1’s small vessels 
of lungs’ hilar lymph nodes.
In conclusion, IHC findings induce to identify SARS-CoV-2 like a virus with ability to deeply alter 
immune system’s functions and coagulation homeostasis. The abovementioned IHC features of 
lymphocytes, cytotoxic cells, and platelets should be taken into account by pathologists who 
approaches autopsies of SARS-CoV-2 infected individuals in order to better understand SARS-
CoV-2 pathophysiology process and to correctly identify causes/contributing factors of death in 
forensic routine.  
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Figures
Fig. 1 - IHC images of cytotoxic cell and T-lymphocyte recruitment.
A. Patient 2, IHC for TIA1 molecule (190x) – Massive recruitment of cytotoxic cells in spleen red 
pulp; B. Patient 2, IHC for CD3 molecule (90x) – Extensive perivascular recruitment of T-cells in 
lung parenchyma; C. Patient 1, IHC for TIA1 molecule (170x) – peri/intra-vascular recruitment of 
cytotoxic cells in lung parenchyma.
Fig. 2 - IHC images of platelet aggregates in vessels
A. Patient 1, IHC for CD61 molecule (120x) – diffuse platelet aggregation all along the internal 
endothelial layer of lung small vessel walls; B. Patient 2, IHC for CD61 molecule (60x) – platelet 
aggregation all along the internal endothelial layer of a small lung vessel; C. Patient 2, IHC for 
CD61 molecule (180x) – platelet aggregation all along the internal endothelial layer of a myocardial 
small vessel; D. Patient 2, IHC for CD61 molecule (190x) – platelet aggregation which nearly 
occludes the lumen of a renal small vessel.
Fig. 3 - IHC images of diffuse platelet aggregates in small vessels of a lymph node of 
pulmonary hilum
Patient 1, IHC for CD61 molecule (50x) – diffuse platelet aggregates in multiple small vessels
Fig. 4 - Comparative images of lungs, heart, spleen, and kidneys at histology (hematoxylin and 
eosin stain)
A. Patient 2, spleen (40x); B. Patient 2, heart (100x); C. Patient 2, kidney (90x); D. Patient 1, lung 
(50x)
Highlights
- SARS-CoV-2 infection can evolve determining sudden dyspnea and death without hospitalization 
and/or a nasopharyngeal swab
- These cases can need the intervention of forensic pathologists in order to identify causes of death 
and to clarify malpractice claims
- It would be useful to identify immunohistochemistry patterns of SARS-CoV-2 deaths
- The authors described immunohistochemistry findings of two Patients: perivascular recruitment of 
T-cells in lung parenchyma, massive activation of cytotoxic cells (especially in spleen’s 
parenchyma), and diffuse platelet aggregation in medium/small vessels
- They analyzed these data in the light of the scientific literature, pointing out meaningful 
immunohistochemistry patterns


